Mr. Guido Baechler reports

TELO GENOMICS ANNOUNCES NON-BROKERED PRIVATE PLACEMENT OF CONVERTIBLE DEBENTURES FOR UP TO $1,200,000

Telo Genomics Corp. has arranged a non-brokered private placement offering of secured convertible debentures for gross proceeds of up to $1.2-million. The company may pay finders' fees in connection with the offering.

The debentures will bear interest at a rate of 15 per cent per annum, compounded quarterly, and will mature nine months after the closing date. The principal amount of the debentures may, at the holder's election, at any time before the maturity date, be converted into common shares of the company at a conversion price of five cents per common share. For every $100,000 of convertible debentures issued, Telo Genomics will issue two million detachable warrants. Each warrant will be exercisable to acquire one common share at an exercise price of eight cents per share for a period of 12 months from the closing date. The company has no right to prepay the debentures prior to the maturity date.

The proceeds raised from the offering are expected to be used for lab trials and general working capital.

The offering is subject to certain conditions, including, but not limited to, receipt of all necessary approvals from the TSX Venture Exchange.

The debentures, warrants and any securities issuable upon conversion or exercise will be subject to a four-month hold period in accordance with applicable Canadian securities laws.

About Telo Genomics Corp.

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining the Telo Genomics team's considerable expertise in quantitative analysis of 3-D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of the company's proprietary technology have been substantiated in 160-plus peer-reviewed publications and in 30-plus clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. The company's lead application, Telo-MM, is being developed to provide important, actionable information to medical professionals in the treatment of multiple myeloma, a deadly form of blood cancer.

We seek Safe Harbor.